Case report: Responses to the combination of gemcitabine with sirolimus in two patients with TSC-mutated sarcomas

Figures

• 

  Figure 1. Representative Hematoxylin & Eosin Slide of Outside Referral Biopsy from Patient 1. Sample collected in February 2020, pre-treatment, image is at 10X magnification.

• 

  Figure 2. Timeline of Treatments of Patient 1. Treatment lines are displayed chronologically, with imaging assessments at baseline, at time of best response to treatment, and at time of end of treatment for each line of treatment. Initial pathology diagnostic and molecular profiles are displayed. IHC, immunohistochemistry; LOF, loss-of-function; MSI, microsatellite instable; PD, Progressive Disease; PR, Partial Response; TMB, tumor mutational burden; VAF, variant allele fraction.

• 

  Figure 3. Representative Hematoxylin & Eosin Slide of Outside Referral Biopsy from Patient 2 Samples collected in December 2020 (A), January 2021 (B), and March 2021 (C), all pre-treatment, image is at 10X magnification.

• 

  Figure 4. Timeline of Treatments of Patient 2. Treatment lines are displayed chronologically, with imaging assessments at baseline, at time of best response to treatment, and at time of end of treatment for each line of treatment. Initial pathology diagnostic and molecular profiles are displayed. HPF, high power field; IHC, immunohistochemistry; LOF, loss-of-function; MSI, microsatellite instable; PD, Progressive Disease; PR, Partial Response; SD, Stable Disease; TMB, tumor mutational burden; VAF, variant allele fraction.